CM Management’s Atea Pharmaceuticals AVIR Stock Holding History

CM Management’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.65M	Hold	355,000	–	–	1.05%	42
2026 Q1	$1.91M	Hold	355,000	–	–	1.6%	18
2025 Q4	$1.27M	Sell	355,000 -145,000	-29%	-$461K	1.07%	34
2025 Q3	$1.45M	Hold	500,000	–	–	1.21%	33
2025 Q2	$1.8M	Hold	500,000	–	–	1.64%	24
2025 Q1	$1.5M	Buy	500,000 +200,000	+67%	+$624K	1.5%	30
2024 Q4	$1M	Buy	300,000 +30,000	+11%	+$99.7K	0.9%	42
2024 Q3	$905K	Hold	270,000	–	–	0.72%	49
2024 Q2	$894K	Hold	270,000	–	–	0.82%	43
2024 Q1	$1.09M	Hold	270,000	–	–	0.92%	43
2023 Q4	$824K	Sell	270,000 -5,000	-2%	-$15.1K	0.66%	46
2023 Q3	$825K	Buy	275,000 +25,000	+10%	+$85.1K	0.88%	40
2023 Q2	$935K	Sell	250,000 -75,000	-23%	-$281K	0.91%	35
2023 Q1	$1.09M	Buy	325,000 +50,000	+18%	+$203K	1.29%	32
2022 Q4	$1.32M	Buy	275,000 +25,000	+10%	+$126K	1.58%	20
2022 Q3	$1.42M	Buy	250,000 +50,000	+25%	+$383K	1.59%	22
2022 Q2	$1.42M	Hold	200,000	–	–	1.51%	26
2022 Q1	$1.44M	Buy	200,000 +100,000	+100%	+$679K	1.21%	30
2021 Q4	$894K	Hold	100,000	–	–	0.68%	51
2021 Q3	$3.51M	Buy	100,000 +10,000	+11%	+$277K	2.61%	7
2021 Q2	$1.93M	Buy	+90,000	New	+$2.7M	1.4%	20

Other funds holding AVIR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management's AVIR Position: Q2 2026 in Review

CM Management held its Atea Pharmaceuticals (AVIR) position steady in Q2 2026 at 355,000 shares worth $1.65M. The position accounts for 1.05% of the portfolio, ranked #42.

CM Management first reported a position in AVIR in Q2 2021 and has held it in 21 quarters since. The position peaked at $3.51M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

CM Management held 355,000 shares of Atea Pharmaceuticals worth $1.65M as of Q2 2026.
CM Management left its Atea Pharmaceuticals share count unchanged in Q2 2026.
Atea Pharmaceuticals made up 1.05% of CM Management's portfolio in Q2 2026, its #42 holding.
CM Management first reported a position in Atea Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
CM Management's Atea Pharmaceuticals position peaked at $3.51M in Q3 2021.
125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on CM Management's 13F filing for Q2 2026, filed 13 Aug 2026.